Focused On-demand Library for Receptor for retinol uptake STRA6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9BX79

UPID:

STRA6_HUMAN

Alternative names:

Retinol-binding protein receptor STRA6; Stimulated by retinoic acid gene 6 protein homolog

Alternative UPACC:

Q9BX79; A8K7F1; B7Z5M9; B7Z862; D3DW54; F5GYI8; I3L1G8; Q6PJF8; Q71RB9; Q7L9G1; Q7Z3U9; Q8TB21; Q9BX78; Q9H9U8

Background:

Receptor for retinol uptake STRA6, also known as Retinol-binding protein receptor STRA6, plays a pivotal role in vitamin A homeostasis. It facilitates the transport of retinol across cell membranes, contributing to vital processes in the eye and under conditions of dietary vitamin A deficiency. STRA6's interaction with retinol-binding proteins and its involvement in signaling pathways underscore its importance in cellular responses to insulin and vitamin A metabolism.

Therapeutic significance:

STRA6's link to Microphthalmia, syndromic, 9, a condition characterized by severe eye formation disorders and pulmonary abnormalities, highlights its therapeutic potential. Understanding the role of STRA6 could open doors to potential therapeutic strategies for treating or managing this rare disease.